Heat shock protein: Difference between revisions

Intracellular heat shock proteins are highly expressed in cancerous cells and are essential to the survival of these cell types due to presence of mutated and over-expressed oncogenes.<ref name=":4" /> Many HSPs can also promote invasiveness and metastasis formation in tumours, block apoptosis, or promote resistance to anti-cancer drugs.<ref>{{cite journal | vauthors = Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S | title = Heat Shock Proteins and Cancer | journal = Trends in Pharmacological Sciences | volume = 38 | issue = 3 | pages = 226–256 | date = March 2017 | pmid = 28012700 | doi = 10.1016/j.tips.2016.11.009 }}</ref><ref name=":5" /> Hence [[small molecule]] [[HSP inhibitor|inhibitors of HSPs]], especially [[Hsp90]] show promise as anticancer agents.<ref name="pmid18045130">{{cite journal | vauthors = Didelot C, Lanneau D, Brunet M, Joly AL, De Thonel A, Chiosis G, Garrido C | title = Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins | journal = Current Medicinal Chemistry | volume = 14 | issue = 27 | pages = 2839–47 | year = 2007 | pmid = 18045130 | doi = 10.2174/092986707782360079 }}</ref> The potent Hsp90 inhibitor [[17-N-Allylamino-17-demethoxygeldanamycin|17-AAG]] was in [[clinical trial]]s for the treatment of several types of cancer, but for various reasons unrelated to efficacy did not go on to Phase 3.<ref name="pmid16842157">{{cite journal | vauthors = Solit DB, Rosen N | title = Hsp90: a novel target for cancer therapy | journal = Current Topics in Medicinal Chemistry | volume = 6 | issue = 11 | pages = 1205–14 | year = 2006 | pmid = 16842157 | doi = 10.2174/156802606777812068 }}</ref><ref>{{cite journal|last1=The Myeloma Beacon Staff|first1=-|title=Bristol-Myers Squibb Halts Development of Tanespimycin|journal=The Myeloma Beacon|date=22 Jul 2010|url=http://www.myelomabeacon.com/news/2010/07/22/tanespimycin-development-halted/|access-date=9 January 2018}}</ref> HSPgp96 also shows promise as an anticancer treatment and is currently in clinical trials against non-small cell lung cancer.<ref>{{cite journal|url=http://clinicaltrials.gov/ct2/show/NCT01504542?term=heat+biologics&rank=1|title=Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov|date=20 November 2013|access-date=10 April 2018}}</ref>